Auteri G.; Bartoletti D.; Di Pietro C.; Sutto E.; Mazzoni C.; Romagnoli A.D.; Vianelli N.; Lazzarotto T.; Cavo M.; Palandri F., Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity, «LEUKEMIA RESEARCH», 2022, 116, Article number: 106819 , pp. 0 - 0 [Scientific article]
Parisi, Sarah; Ruggeri, Loredana; Dan, Elisa; Rizzi, Simonetta; Sinigaglia, Barbara; Ocadlikova, Darina; Bontadini, Andrea; Giudice, Valeria; Urbani, Elena; Ciardelli, Sara; Sartor, Chiara; Cristiano, Gianluca; Nanni, Jacopo; Zannoni, Letizia; Chirumbolo, Gabriella; Arpinati, Mario; Lewis, Russell E.; Bonifazi, Francesca; Marconi, Giovanni; Martinelli, Giovanni; Papayannidis, Cristina; Paolini, Stefania; Velardi, Andrea; Cavo, Michele; Lemoli, Roberto M.; Curti, Antonio, Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters, «FRONTIERS IN IMMUNOLOGY», 2022, 12, pp. 1 - 6 [Scientific article]Open Access
Parisi S.; Ruggeri L.; Dan E.; Rizzi S.; Sinigaglia B.; Ocadlikova D.; Bontadini A.; Giudice V.; Urbani E.; Ciardelli S.; Sartor C.; Cristiano G.; Nanni J.; Zannoni L.; Chirumbolo G.; Arpinati M.; Lewis R.E.; Bonifazi F.; Marconi G.; Martinelli G.; Papayannidis C.; Paolini S.; Velardi A.; Cavo M.; Lemoli R.M.; Curti A., Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters, «FRONTIERS IN IMMUNOLOGY», 2022, 12, Article number: 804988 , pp. 1 - 6 [Scientific article]Open Access
Girmenia C.; Cavo M.; Corso A.; Di Raimondo F.; Musto P.; Offidani M.; Petrucci M.T.; Rosato A.; Barosi G., Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2022, 172, Article number: 103623 , pp. 0 - 0 [Scientific article]
Schjesvold F.H.; Dimopoulos M.-A.; Delimpasi S.; Robak P.; Coriu D.; Legiec W.; Pour L.; Spicka I.; Masszi T.; Doronin V.; Minarik J.; Salogub G.; Alekseeva Y.; Lazzaro A.; Maisnar V.; Mikala G.; Rosinol L.; Liberati A.M.; Symeonidis A.; Moody V.; Thuresson M.; Byrne C.; Harmenberg J.; Bakker N.A.; Hajek R.; Mateos M.-V.; Richardson P.G.; Sonneveld P.; Schjesvold F.; Nikolayeva A.; Tomczak W.; Pour L.; Spicka I.; Mikala G.; Rosinol L.; Konstantinova T.; Gatt M.; Illes A.; Abdulhaq H.; Dungarwalla M.; Grosicki S.; Hajek R.; Leleu X.; Myasnikov A.; Richardson P.G.; Avivi I.; Deeren D.; Gironella M.; Hernandez-Garcia M.T.; Martinez Lopez J.; Newinger-Porte M.; Ribas P.; Samoilova O.; Voog E.; Arnao-Herraiz M.; Carrillo-Cruz E.; Corradini P.; Dodlapati J.; Granell Gorrochategui M.; Huang S.-Y.; Jenner M.; Karlin L.; Kim J.S.; Kopacz A.; Medvedeva N.; Min C.-K.; Mina R.; Palk K.; Shin H.-J.; Sohn S.K.; Tache J.; Anagnostopoulos A.; Arguinano J.-M.; Cavo M.; Filicko J.; Garnes M.; Halka J.; Herzog-Tzarfati K.; Ipatova N.; Kim K.; Krauth M.-T.; Kryuchkova I.; Lazaroiu M.C.; Luppi M.; Proydakov A.; Rambaldi A.; Rudzianskiene M.; Yeh S.-P.; Alcala-Pena M.M.; Alegre Amor A.; Alizadeh H.; Bendandi M.; Brearton G.; Brown R.; Cavet J.; Dally N.; Egyed M.; Hernandez-Rivas J.A.; Kaare A.; Karsenti J.-M.; Kloczko J.; Kreisle W.; Lee J.-J.; Machherndl-Spandl S.; Manda S.; Moiseev I.; Moreb J.; Nagy Z.; Nair S.; Oriol-Rocafiguera A.; Osswald M.; Otero-Rodriguez P.; Peceliunas V.; Plesner T.; Rey P.; Rossi G.; Stevens D.; Suriu C.; Tarella C.; Verlinden A.; Zannetti A., Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study, «THE LANCET. HAEMATOLOGY», 2022, 9, pp. 98 - 110 [Scientific article]
Manasanch E.E.; Beksac M.; Cavo M.; Knauf W.; Tsukada N.; Tekle C.; Zhao Z.; Martin T., MM-086 Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2022, 22, pp. S405 - S406 [Scientific article]
Gozzetti A.; Guarnieri A.; Zamagni E.; Zakharova E.; Coriu D.; Bittrich M.; Pika T.; Tovar N.; Schutz N.; Ciofini S.; Pena C.; Rocchi S.; Rassner M.; Avivi I.; Waszczuk-Gajda A.; Chhabra S.; Usnarska-Zubkiewicz L.; Gonzalez-Calle V.; Mateos M.-V.; Bocchia M.; Bigi F.; Fullgraf H.; Bhasin-Chhabra B.; Gentile M.; Davila J.; Vesole D.H.; Cavo M.; Thapa B.; Crusoe E.; Einsele H.; Legiec W.; Charlinski G.; Jurczyszyn A., Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors, «AMERICAN JOURNAL OF HEMATOLOGY», 2022, 97, pp. 877 - 884 [Scientific article]Open Access
Monaldi C.; de Santis S.; Mancini M.; Papayannidis C.; Sartor C.; Rondoni M.; Bruno S.; Cavo M.; Soverini S., MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2022, 22, pp. S328 - S328 [Scientific article]
De Santis S.; Monaldi C.; Mancini M.; Bruno S.; Cavo M.; Soverini S., Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia, «ONCOTARGETS AND THERAPY», 2022, 15, pp. 103 - 116 [Scientific article]Open Access
Larocca A.; Leleu X.; Touzeau C.; Blade J.; Paner A.; Mateos M.-V.; Cavo M.; Maisel C.; Alegre A.; Oriol A.; Raptis A.; Rodriguez-Otero P.; Mazumder A.; Laubach J.; Nadeem O.; Sandberg A.; Orre M.; Torrang A.; Bakker N.A.; Richardson P.G., Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study, «BRITISH JOURNAL OF HAEMATOLOGY», 2022, 196, pp. 639 - 648 [Scientific article]
Palandri F.; Bartoletti D.; Iurlo A.; Bonifacio M.; Abruzzese E.; Caocci G.; Elli E.M.; Auteri G.; Tiribelli M.; Polverelli N.; Miglino M.; Heidel F.H.; Tieghi A.; Benevolo G.; Beggiato E.; Fava C.; Cavazzini F.; Pugliese N.; Binotto G.; Bosi C.; Martino B.; Crugnola M.; Ottaviani E.; Micucci G.; Trawinska M.M.; Cuneo A.; Bocchia M.; Krampera M.; Pane F.; Lemoli R.M.; Cilloni D.; Vianelli N.; Cavo M.; Palumbo G.A.; Breccia M., Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis, «CANCER», 2022, 128, pp. 2449 - 2454 [Scientific article]Open Access
Mancini M.; De Santis S.; Monaldi C.; Castagnetti F.; Lonetti A.; Bruno S.; Dan E.; Sinigaglia B.; Rosti G.; Cavo M.; Gugliotta G.; Soverini S., Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors, «FRONTIERS IN ONCOLOGY», 2022, 12, Article number: 901132 , pp. 1 - 13 [Scientific article]Open Access
Cavo M.; Gale R.P., Prof. Sante Tura: father of modern Italian Haematology 20 May, 1929 to 12 October, 2021, «BONE MARROW TRANSPLANTATION», 2022, 57, pp. 1048 - 1049 [Scientific article]
Cavo, M; San-Miguel, J; Usmani, SZ; Weisel, K; Dimopoulos, MA; Avet-Loiseau, H; Paiva, B; Bahlis, NJ; Plesner, T; Hungria, V; Moreau, P; Mateos, MV; Perrot, A; Iida, S; Facon, T; Kumar, S; van de Donk, NWCJ; Sonneveld, P; Spencer, A; Krevvata, M; Heuck, C; Wang, JP; Ukropec, J; Kobos, R; Sun, S; Qi, M; Munshi, N, Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA, «BLOOD», 2022, 139, pp. 835 - 844 [Scientific article]
Corradi G.; Bassani B.; Simonetti G.; Sangaletti S.; Vadakekolathu J.; Fontana M.C.; Pazzaglia M.; Gulino A.; Tripodo C.; Cristiano G.; Bandini L.; Ottaviani E.; Ocadlikova D.; Piccioli M.; Martinelli G.; Colombo M.P.; Rutella S.; Cavo M.; Ciciarello M.; Curti A., Release of IFNg by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells, «CLINICAL CANCER RESEARCH», 2022, 28, pp. 3141 - 3155 [Scientific article]
